UK Rejects Rx-To-OTC Switch Of Overactive Bladder Treatment
Maxwellia’s application to switch to non-prescription status in the UK Aquiette (oxybutynin hydrochloride) for the treatment of overactive bladder has been rejected by MHRA following a public consultation.
You may also be interested in...
People On The Move: Appointments At AESGP, Alliance Pharma, FSE, Venture Life
A round-up of the latest appointments in Europe's consumer health industry: AESGP names Haleon's Workman as president; Alliance Pharma shareholders re-elect board; Food Supplements Europe re-elects Stada's Šímová as chair; and Venture Life announces departure of co-Founder and CCO Daly.
Sweden Drops Plans For Max Levels In Supplements After Commission Consultation
Sweden will not introduce proposed limits for vitamin D and iodine in dietary supplements after the European Commission warned it would create a disproportionate barrier to trade with other EU member states.
Nestlé's Iron Deficiency Supplement Among Latest EU Novel Food Authorizations
A new source of iron manufactured by Nestlé is one of four novel foods to receive authorization by the European Commission for use in dietary supplements.